Strong Buy · 80/100Jul 13, 6:56 PM EDT
Biogen and Eisai Win FDA Nod for At-Home Subcutaneous Leqembi Dosing
BIIBESALF
The FDA approved Biogen (BIIB) and Eisai's (ESALF) subcutaneous Leqembi Iqlik (lecanemab) for both initiation and maintenance dosing, enabling at-home administration. This expands patient access and convenience, potentially boosting adoption and revenue for th…
- ▹FDA approval of subcutaneous version for initiation and maintenance dosing
- ▹At-home use expands patient access and convenience
Neutral · 64/100Jul 13, 12:23 PM EDT
BioMarin's Voxzogo Full Approval Bid Accepted by FDA
BMRN
BioMarin Pharmaceutical's supplemental New Drug Application (sNDA) for full approval of its achondroplasia drug Voxzogo (vosoritide) has been accepted by the FDA, with a decision deadline set for February 28, 2027. The application, supported by three long-term…
- ▹sNDA accepted for full approval, but action date far out (2027) and no accelerated path; single-asset focus limits tech score.
High Risk · 47/100Jul 13, 7:36 PM EDT
HHS-VA Pact Signals Potential Catalyst for Psychedelic Drug Developers
CMPSATAIGHRS
The Department of Health and Human Services and the Veterans Administration signed a memorandum of understanding to collaborate on research and clinical development of psychedelic-based treatments for veterans with mental health conditions. This government bac…
- ▹MOU between HHS and VA supports psychedelic research but no direct FDA action; single-asset risk for most psychedelic companies
High Risk · 37/100Jul 13, 4:46 PM EDT
Erasca Files for $500M Public Stock Offering
ERAS
Erasca (ERAS) announced a $500 million underwritten public offering of common stock. The capital raise could dilute existing shareholders but provides funds to advance its pipeline of RAS-targeted cancer therapies.
- ▹Massive dilution from $500M stock offering
- ▹Single-asset company with no approved products
High Risk · 37/100Jul 13, 4:07 PM EDT
Q32 Bio Launches $200M Public Offering of Common Stock and Pre-Funded Warrants
QTTB
Q32 Bio (QTTB) announced a $200M underwritten public offering of common stock and pre-funded warrants. The offering may dilute existing shareholders, but the capital raise could support the company's pipeline development. Investors should monitor the offering'…
- ▹Dilutive offering of $200M signals cash need and potential runway concerns
- ▹Single-asset micro-cap with no clear regulatory or commercial catalysts
High Risk · 0/100Jul 13, 4:26 PM EDT
Matinas BioPharma Merges with GH Power to Form NYSE-Listed Clean Energy Firm
MTNB
Matinas BioPharma (MTNB) has entered into a business combination agreement with GH Power to create a new publicly traded company, GH Power International, focused on critical minerals and clean energy. The deal will result in a NYSE listing, marking a strategic…
- ▹Company pivoting from biotech to clean energy, no relevance to biotech investment framework.